Altria's volumes fell 3.2% last quarter and the board raised the dividend 4.7% four days before we priced the company. Not despite the decline — because of how the decline is being run. As at our X-Ray of 31 August 2026 at $68.65, this was the sixty-first dividend increase in fifty-seven years, from a company that has been selling fewer cigarettes for most of that time.
That combination is the most under-examined idea in investing. Everybody knows how to think about a growing business. Almost nobody is taught how to value one that will be smaller every year forever — and there are more of them than anyone admits.
Four moves, executed for thirty years
The whole model in one line. Cigarettes are addictive, branded and bought habitually, which gives pricing power that ordinary consumer goods can only envy. As at 31 August 2026, US volumes were down 3.2% — 4.5% adjusted — and revenue was still within about 4% of its 2016 level.
A smaller business should be a cheaper one. Altria's operating margin went from 45.3% to 55.9% — fifty-six cents of operating profit on every dollar of revenue, which is among the highest of any company we have examined, in any industry.
If the pie shrinks slowly and the number of slices shrinks faster, each slice grows. The share count is down about 14%. This is the quiet half of the return, and the half most income investors never count.
A declining business has no good use for retained cash, so retaining it is a mistake. Paying it out is not shareholder-friendliness — it is the only honest capital allocation available.
This is what a business in permanent decline looks like when it is run properly. The question is only whether you are paid enough to own one.
Step five is where the money dies
Management refuses the premise and goes shopping for a future
Every declining business eventually produces a chief executive who cannot accept the job description. The cash is enormous, the ending is unflattering, and buying a growth story is far more satisfying than administering a shrinkage. This is where the shareholders' money goes.
Altria paid $12.8 billion for JUUL. Our August report carried it at $450 million. That is not a bad quarter — it is roughly a fifth of the company's market value at the time, converted into nothing. It then bought NJOY, whose vape products a rival has had banned from the United States on patent grounds.
British American Tobacco ran the same play with a different hand. Our 2 July 2026 X-Ray at $60.56 found £87 billion of acquisition goodwill on the balance sheet and a 2023 impairment of its US brands — the accounting admission that it had paid for a future that did not arrive.
In both cases the core business did its job perfectly well. The losses came from the attempt to escape it. When you own a declining franchise, the largest single risk on your list is not the decline — it is management's reaction to the decline, and it does not show up in any ratio.
Same trade, two different bets
As at our reports — Altria 31 August 2026, BAT 2 July 2026
| Altria (MO) | British American Tobacco (BTI) | |
|---|---|---|
| Our overall score | 5.6 | 6.2 |
| Yield at our price | 6.47% on $68.65 | ~5.3% on $60.56 |
| Multiple | 12.1× the 2026 guidance midpoint | ~13× earnings |
| Geography | United States only — no diversification | International — many markets, many regulators |
| The balance sheet mark | Negative shareholders' equity | £87bn of acquisition goodwill |
| The capital-allocation scar | JUUL: $12.8bn → $450m | 2023 impairment of the US brands |
The difference that matters is not the yield. It is that BAT sells in many countries, so no single regulator can end it, while Altria's entire business sits inside one jurisdiction — which cuts both ways. One regulator is a concentrated risk, and it is also a known, slow-moving, heavily litigated one that has been failing to kill this industry for sixty years.
Our scores reflected that: 6.2 for BAT, 5.6 for Altria. Neither is high. Both are honest about what they are — the verdict on BAT was "a wonderful business in a business I would not want to own", and on Altria, "there is no version of this where the volumes go up".
How do you value an ending?
Here is the arithmetic nobody enjoys. If a business shrinks 3% a year and pays you 6.5%, your return depends entirely on how long the shrinking takes and what management does with the cash on the way. There is no terminal growth rate to fall back on and no multiple expansion to hope for. The dividend is not a bonus on top of the return. It is the return.
Which makes the analysis unusually clean. You are not forecasting a future — you are pricing a runway, and asking two questions: does the cash last longer than the market thinks, and will the people running it resist the urge to spend it on an escape. On the first question, tobacco has beaten the sceptics for decades. On the second, it has a documented record of failure measured in tens of billions.
Business, moat, management, the numbers, valuation and an honest verdict.
What this has to do with companies you actually own
Tobacco is the clearest case, not the only one. Anything facing a structural decline — print, landlines, coal, parts of retail banking, eventually several things that look like growth today — faces the same four moves and the same step five. The checklist travels:
- Is price outrunning volume? If revenue is roughly flat while units fall, the pricing power is real. If revenue is falling with volume, the decline has already stopped being managed.
- Is the margin rising as the business shrinks? A declining business that is not getting more efficient is being harvested badly.
- Is the share count falling faster than the profit? This is where a shrinking business quietly produces a growing per-share result.
- What did they buy last? The single most predictive question. Look at the last three acquisitions and what they are carried at now.
A business that will be smaller every year can still be a fine investment. It just has to be priced as what it is, and run by people who have accepted what it is. The second condition is much rarer than the first.
Frequently asked
How can a company grow profits while selling less every year?
By raising price faster than it loses volume, cutting cost as the business shrinks, and retiring shares so the same profit is split fewer ways. Altria's revenue as at our 31 August 2026 report was within about 4% of its 2016 level, while its operating margin went from 45.3% to 55.9% and its share count fell about 14%. Profit per share rose out of a business that got smaller.
What eventually breaks a managed decline?
The moment price increases stop outrunning volume declines. Each rise pushes a few more customers out, so the strategy consumes the very base it depends on. It works for a remarkably long time and then it does not work at all — and the company usually finds out a year after its customers do.
Is Altria's dividend safe?
On the figures in our 31 August 2026 X-Ray, the $4.44 annual rate was covered about 1.12 times by free cash flow at a 6.47% yield — thin but real cover, from a business with a 55.9% operating margin. The board raised the rate 4.7% on 27 August, its 61st increase in 57 years. The risk is not this year's cover; it is what the cover looks like after several more years of falling volumes.
Why is Altria's shareholders' equity negative?
Because it has returned more to shareholders over the years, through dividends and buybacks, than the accounting value of what it retained. For a company with heavy assets that would be distress. For one whose value is a brand portfolio that carries almost no book value, it is a bookkeeping outcome, not a solvency signal. What matters is whether cash covers the obligations, not what the balance sheet nets to.